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Abstract
The urokinase‐type plasminogen activator (uPA) receptor (uPAR) participates to the
mechanisms causing renal damage in response to hyperglycaemia. The main function
of uPAR in podocytes (as well as soluble uPAR ‐(s)uPAR‐ from circulation) is to regu-
late podocyte function through αvβ3 integrin/Rac‐1. We addressed the question of
whether blocking the uPAR pathway with the small peptide UPARANT, which inhi-
bits uPAR binding to the formyl peptide receptors (FPRs) can improve kidney lesions
in a rat model of streptozotocin (STZ)‐induced diabetes. The concentration of sys-
temically administered UPARANT was measured in the plasma, in kidney and liver
extracts and UPARANT effects on dysregulated uPAR pathway, αvβ3 integrin/Rac‐1
activity, renal fibrosis and kidney morphology were determined. UPARANT was
found to revert STZ‐induced up‐regulation of uPA levels and activity, while uPAR on
podocytes and (s)uPAR were unaffected. In glomeruli, UPARANT inhibited FPR2
expression suggesting that the drug may act downstream uPAR, and recovered the
increased activity of the αvβ3 integrin/Rac‐1 pathway indicating a major role of
uPAR in regulating podocyte function. At the functional level, UPARANT was shown
to ameliorate: (a) the standard renal parameters, (b) the vascular permeability, (c) the
renal inflammation, (d) the renal fibrosis including dysregulated plasminogen‐plasmin
system, extracellular matrix accumulation and glomerular fibrotic areas and (e) mor-
phological alterations of the glomerulus including diseased filtration barrier. These
results provide the first demonstration that blocking the uPAR pathway can improve
diabetic kidney lesion in the STZ model, thus suggesting the uPA/uPAR system as a
promising target for the development of novel uPAR‐targeting approaches.
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1 | INTRODUCTION
Diabetic nephropathy (DN) is a microvascular complication of dia-
betes leading to end‐stage renal disease that is difficult to handle
despite strict glycaemic control and targeted therapies, thus indicat-
ing the paramount importance to develop novel treatments. DN can
be reproduced in the rat model of type‐1 diabetes induced by strep-
tozotocin (STZ)1 with main alterations that are established 4 weeks
after diabetes onset.2 They include glomerular hypertrophy and
altered filtration barrier that is associated to increased albumin and
creatinine excretion.3 In the medulla, increased glomerular filtration
results in up‐regulated levels of the main transporter proteins
involved in urine concentration among which aquaporin 2 (AQP2)
concurs to prevent excessive water loss.4,5 At the glomerular level,
additional alterations include an increased mesangial area and renal
fibrosis induced by excessive accumulation of extracellular matrix
(ECM) presumably because of inflammatory processes activated by
transcriptional regulators of inflammation‐related genes.6,7
Major players in the diabetes‐associated renal fibrosis include
members of the plasminogen (Plg)‐plasmin system that consists of
the circulating zymogen Plg and its activators including the uroki-
nase‐type plasminogen activator (uPA), a secreted protease that,
through the binding to its receptor (uPAR), converts Plg into plasmin
that promotes ECM degradation either directly or indirectly through
the activation of metalloproteinases (MMPs).8 uPA is a secreted pro-
tease, while uPAR is expressed by glomerular cells, resident fibrob-
lasts and cells of the collecting ducts.9 In rodent models of DN, uPA
and uPAR are both up‐regulated in glomerular cells including podo-
cytes suggesting that dysfunction of the uPA/uPAR system may be
associated with kidney disease.10 In contrast, uPA or uPAR deletion
results in protective effects against kidney injuries.9
uPAR also exists in a soluble form ((s)uPAR) that is generated by
the proteolytic cleavage of the membrane anchored uPAR.10 In par-
ticular, (s)uPAR has been recently demonstrated as a key molecule in
the diseased kidney10,11 and high (s)uPAR levels in the circulation
play a massive role in diabetic kidney disease by regulating podocyte
function.12 Indeed, vast data are available on major role of uPAR in
podocytes (as well as (s)uPAR from circulation) to regulate the activ-
ity of αvβ3 integrin that in turns stimulates small GTPase Rac‐1 pro-
teins, potent regulators of podocyte foot process motility and
effacement.13,14 Altered activity of αvβ3 integrin/Rac‐1 pathway has
been linked to podocyte dysfunction leading to proteinuria12 and
main efforts have been made to clarify mechanisms for uPAR sig-
nalling in regulating podocyte adhesion and migration.10
At the intracellular level, the interaction between uPA and uPAR
is mediated by several membrane proteins including the formyl pep-
tide receptors (FPRs) that are G protein‐coupled receptors involved in
different pathophysiological processes,8 although little is known about
their possible involvement in diabetic kidney disease. The transmem-
brane partnership between uPA, uPAR and FPRs has been reported
as an attractive target for the treatment of DN, the role of drugs
potentially interacting with the uPAR/FPR pathway remains to be
established. The uPAR‐derived tetrapeptide Ac‐L‐Arg‐Aib‐L‐Arg‐L‐
Cα(Me)PheNH2 (UPARANT, recently designated as Cenupatide in the
International Nonproprietary Names nomenclature) has been designed
to compete with N‐formyl‐Met‐Leu‐Phe peptide for binding to FPRs.15
It is endowed with a significant anti‐inflammatory and antiangiogenic
activity both in vitro and in vivo15–20 and has been shown to protect
the retina from pathologic changes induced by diabetic retinopathy
(DR) in animal models.21,22 In this scenario, the possibility that dysreg-
ulated uPAR pathway participates to the pathogenic mechanisms of
DN may add further value to the possible development of UPARANT
as valuable therapy against diabetes complications.
Here, we evaluated the curative effects of subcutaneously admin-
istered UPARANT on diabetic kidney disease using rats with STZ‐
induced diabetes. In the present study, UPARANT concentration in
the plasma, kidney and liver was determined. Protein levels of uPA,
uPAR and FPRs were measured in kidney extracts, while transcripts
of FPRs were determined in isolated glomeruli, before and after
UPARANT treatment. UPARANT effects on (s)uPAR were also evalu-
ated. In addition, protein levels and activity of uPA, Plg, MMP‐2/
MMP‐9 were measured in kidney extracts and in the plasma. Finally,
UPARANT action on αvβ3 integrin and Rac‐1 was explored and its
possible effects on ECM components including fibronectin, collagen I
and collagen IV were considered as an indirect evidence of UPARANT
role in the fibrotic process that was directly evaluated at the histologi-
cal level. At the systemic level, the effects of UPARANT on standard
renal parameters were investigated. In addition, we studied UPARANT
role on vascular permeability (by evaluating occludin, zonula occludens
[ZO]‐1, vascular endothelial growth factor [VEGF] and AQP2) and
renal inflammation (by evaluating the inducible isoform of nitric oxide
synthase [iNOS], intercellular adhesion molecule [ICAM]‐1, nuclear
factor kappa‐light‐chain‐enhancer of activated B cells [NF‐kB], cAMP
response element‐binding protein [CREB] and hypoxia‐inducible factor
[HIF]‐1). Finally, we assessed the effects of UPARANT on DN‐asso-
ciated morphological alterations of the glomerulus including a trans-
mission electron microscopy (TEM) evaluation of the filtration barrier.
2 | MATERIALS AND METHODS
2.1 | Animals and treatment
Eighty‐four male Sprague‐Dawley rats (150‐200 g) were obtained
from Envigo RMS, Italia (S. Pietro al Natisone, Italy). Of them, 63
received a single i.p. injection of 65 mg/kg STZ (Sigma‐Aldrich, St.
Louis, MO, USA) in a citrate buffer solution (0.1 mol/L citric acid and
0.2 mol/L sodium phosphate, pH 4.5). Twenty‐one age‐matched rats
received an equivalent volume of the citrate buffer solution (from
now on referred as controls). Three days after STZ injection, blood
glucose levels were measured. Animals with a plasma glucose
>350 mg/dL were considered diabetic and were used for experimen-
tation. Bodyweights and blood glucose levels were recorded
once a week after the induction of diabetes. Four weeks after
diabetes induction, three control or three STZ rats were used for the
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pharmacokinetics (PK) and the tissue distribution study. To this aim,
rats received a single dose of UPARANT succinate dissolved in PBS
(vehicle) at 20 mg/kg via subcutaneous injection according to a previ-
ous study.22 To investigate a possible therapeutic role of UPARANT,
the drug was administered at 1 or 8 mg/kg daily for 5 days in 15 rats
for each concentration used. Fifteen rats were left untreated while
15 rats were vehicle‐treated. In all experiments, no differences were
observed between untreated and vehicle‐treated rats. UPARANT
dose and regimen were in line with those used in previous stud-
ies.21,22 The rats were kept individually in metabolic cages for
24 hours to collect urine for the measurement of urine output. Sys-
tolic blood pressure was measured by Tail‐cuff Blood Pressure Sys-
tem (IITC MRBP system Life Science, CA, USA). Rats were killed
with 65 mg/kg pentobarbital. Blood was collected in EDTA tubes to
then isolate plasma by centrifugation and kidneys were removed.
Some of them were decapsulated and stored at −80°C until process-
ing for protein extraction. Additional kidneys were fixed with 4%
paraformaldehyde in PBS at 4°C and cryopreserved in 30% sucrose
for immunohistochemistry or histological evaluation. Finally, the cor-
tical part of some kidneys was cut and fixed in 4% glutaraldehyde
and 1% osmium tetroxide for TEM evaluation. Procedures involving
animals were carried out in compliance with the Italian guidelines for
animal care (DL 26/14) and the European Communities Council
Directive (2010/63/UE). Procedures were approved by the Ethical
Committee in Animal Experiments of the University of Pisa.
2.2 | Pharmacokinetics study and UPARANT tissue
distribution
PK and UPARANT tissue distribution were as previously described.21
Briefly, for plasma PK, a volume of 0.2 mL blood was extracted at
fixed time intervals (0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after
dose) from the femoral vein. Blood was centrifuged (12 000 g for
20 minutes) and plasma was treated with 1% formic acid in metha-
nol. Samples were stored at −80°C. The animals used for the PK
study were killed at 24 hours. Kidneys and livers were dissected and
processed with 1% formic acid in methanol. The concentration of
UPARANT was evaluated via LC‐MS/MS.
2.3 | Evaluation of albuminuria, creatininuria,
plasma creatinine and blood urea nitrogen
Urine albumin was measured with the Albumin rat ELISA kit (Abcam,
Cambridge, UK). Urine and plasma creatinine were measured with
the Creatinine assay kit (Abcam). Blood urea nitrogen (BUN) was
evaluated with the BUN colorimetric detection kit (Thermo Fisher
Scientific, Waltham, MA, USA).
2.4 | Western blotting
Whole kidneys homogenized using RIPA buffer supplemented with a
cocktail of protease and phosphatase inhibitors were processed for
protein extraction. They were used to investigate the effect of
UPARANT on the uPAR pathway (uPA, uPAR and FPRs), αvβ3 inte-
grin, the phosphorylated form of β3 integrin, Rac‐1, Plg, plasmin,
MMPs (MMP‐2 and MMP‐9), markers of fibrosis (fibronectin, colla-
gen I and collagen IV), markers of either vascular permeability (ZO‐1,
occludin and VEGF) or inflammation (iNOS, ICAM‐1, phosphorylated
and total forms of the p65 subunit of NF‐κB and of CREB, and the α
subunit of HIF‐1 [HIF‐1α]). The effect of UPARANT on AQP2 was
determined in samples of the medulla that was dissected from the
renal cortex (3 medullas for each experimental condition). In all experi-
ments, homogenates were centrifuged at 22 000 g for 15 minutes at
4°C. Protein concentration was evaluated using the Micro BCA
method (Thermo Fisher Scientific). Equal amounts of proteins were
separated by 4%‐20% SDS‐polyacrylamide gel electrophoresis gels
(TGX Stain‐free precast gels; Bio‐Rad Laboratories, Hercules, CA, USA)
and transferred onto nitrocellulose membrane using a Bio‐Rad Trans‐
Blot Turbo System. The membranes were probed using the primary
antibodies listed in Table S1. After the incubation with the appropriate
horseradish‐peroxidase‐conjugated secondary antibody, bands were
visualized using the Clarity Western ECL substrate with a ChemiDoc
XP imaging system (Bio‐Rad Laboratories). Bands were quantified for
densitometry using the Image Lab software (Bio‐Rad Laboratories) and
normalized to β‐actin, NF‐κB or CREB, as appropriate.
2.5 | Colorimetric assay
The activity of uPA and plasmin was measured using colorimetric
assays. In particular, uPA activity was assayed using the uPA Activity
Assay Kit (Sigma‐Aldrich) while plasmin activity was assayed using Chro-
mozym PL, a plasmin‐specific chromogenic substrate (Sigma‐Aldrich).
2.6 | Fluorogenic assay
The activity of MMPs was assessed using a fluorogenic assay (Inno-
Zyme Gelatinase [MMP‐2/MMP‐9] Activity Assay Kit; Millipore, Bed-
ford, MA, USA). The assay uses a collagen‐like fluorogenic substrate
that, cleaved by MMP‐2/MMP‐9, results in fluorescence increase.
Fluorescence was measured at an excitation wavelength of 320 nm
and an emission wavelength of 405 nm.
2.7 | ELISA
The activity of Rac‐1 was measured using the Rac‐1 Activation Assay
Kit (Cytoskeleton, Inc., Denver, CO, USA), a quantitative ELISA assay
that recognizes the active GTP‐bound form of Rac‐1. Plasma levels
of uPA, (s)uPAR, Plg and MMPs were measured using commercially
available ELISA kits (MyBioSource, San Diego, CA, USA for uPA;
Lifescience Market, Hong Kong for (s)uPAR; Abcam for Plg and
MMP‐2; LSBio, Seattle, WA, USA for MMP‐9).
2.8 | Quantitative real‐time PCR
Kidneys were collected and placed in ice‐cold PBS (pH 7.4) and glo-
meruli were isolated from the cortical area through the passage to
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three consecutive cell strainers (200, 100 and 70 μm; pluriStrainer
set 3, pluriSelect, Leipzig, Germany). The glomeruli retained on the
100 and 70 μm cell strainers were washed, assessed under a light
microscope and used for quantitative real‐time PCR (qPCR) analysis.
qPCR experiments were performed using three independent sam-
ples. Total RNA was extracted using RNeasy Mini Kit (Qiagen,
Valencia, CA, USA). First‐strand cDNA was generated from 1 μg of
total RNA (QuantiTect Reverse Transcription Kit; Qiagen). qPCR
amplification was performed with SsoAdvanced Universal SYBR
Green Supermix (Bio‐Rad Laboratories) on a CFX Connect Real‐
Time PCR detection system and software CFX manager (Bio‐Rad
Laboratories). qPCR primer sets for FPRs were chosen to hybridize
to unique regions of the appropriate gene sequence. Their
sequences were as follows: FPR1 forward 5′‐GTTTCCGCATG
AAACGCACT‐3′; FPR1 reverse 5′‐CATGACCAGGCTGACGATGT‐3′;
FPR2 forward 5′‐GCTTCACAATGCCCATGTCC‐3′; FPR2 reverse 5′‐
ACTCGTAAGGGACGACTGGA‐3′; FPR3 forward 5′‐TCCCTTTCAAC
TGGTTGCCC‐3′; FPR3 reverse 5′‐GCCAATGAGTTGGTTGGCATA‐
3′; Rpl13a forward 5′‐GGATCCCTCCACCCTATGACA‐3′; Rpl13a
reverse 5′‐CTGGTACTTCCACCCGACCTC‐3′. Amplification effi-
ciency was near 100% for each primer pair (Opticon Monitor 3
software; Bio‐Rad Laboratories). Target genes were assayed concur-
rently with Rpl13a, a gene encoding for ribosomal protein L13A.
Samples were compared using the relative threshold cycle (Ct
Method). The increase or decrease (fold change) was determined
relative to control mice after normalization to Rpl13a. All reactions
were performed in triplicate.
2.9 | Histological evaluation
Kidney tissue samples were collected, fixed in 4% paraformaldehyde
for 48 hours and embedded in paraffin. Five‐μm thick sections were
dewaxed and stained with Masson's trichrome stain to detect fibro-
sis or periodic acid‐Schiff (PAS) to outline glomerular structure.
Images were obtained by analysing a minimum of 15 glomerular sec-
tions from each group (five sections/animal) with a light microscope
(Ni‐E, Nikon Europe, Amsterdam, The Netherlands). Glomerular and
mesangial areas were evaluated using the Image J software (NIH,
Bethesda, MD, USA).
2.10 | Evans blue dye leakage
UPARANT effects on vascular permeability were determined by
quantifying Evans blue dye leakage extravasation. Evans blue dye
was dissolved in normal saline (20 mg/mL) and filtered. Anaes-
thetized rats were injected with Evans blue dye through the femoral
vein at 20 mg/kg. Sixty minutes later, each rat was perfused through
the left cardiac ventricle with 15 mL of heparinized saline (4 U/mL)
under constant peristaltic flow (10 mL/min) to purge out the circulat-
ing dye. Then, the kidneys were harvested, dissected and weighed.
The Evans blue dye was extracted with formamide overnight at
65°C and read at 620 nm using a plate reader (Microplate Reader
680 XR; Bio‐Rad Laboratories).
2.11 | Immunofluorescence confocal analysis
Rat kidneys were fixed overnight with 4% paraformaldehyde at 4°C,
cryopreserved in 30% sucrose for 24 hours, and embedded in opti-
mal cutting temperature medium. Thin transverse cryosections
(4 μm) were placed on Superfrost/Plus Microscope Slides (Thermo
Fisher Scientific). The sections were incubated with a rabbit poly-
clonal antibody directed to AQP2 (1:1000 dilution)23 and then with
an AlexaFluor488‐conjugated secondary antibody (Life Technologies,
Carlsbad, CA, USA). Confocal images were obtained with a confocal
laser‐scanning microscope (TSC‐SP2; Leica, Wetzlar, Germany).
2.12 | Transmission electron microscopy
The cortical part of the kidneys was processed according to stan-
dardized procedures for electron microscopy. The sample were cut
into 1 mm3 pieces, fixed in 4% glutaraldehyde (phosphate buffered,
pH 7.2) and 1% osmium tetroxide and embedded in Epon 812
(Sigma‐Aldrich). After ultrathin sectioning, the samples were post-
stained with uranyLess TEM staining solution and examined under a
JEM 1010 electron microscope (Jeol, Tokyo, Japan) at 80 kV. A mini-
mum of 10 glomeruli were analysed from each group (three rats for
each experimental condition) to evaluate the ultrastructural alter-
ations of the glomerular filtration barrier.
2.13 | Data analysis
Statistical significance was evaluated using one‐way ANOVA fol-
lowed by Newman‐Keuls’ multiple comparison posttest. The results
are expressed as mean ± SEM or mean ± SD of three independent
measurements (Prism 5; GraphPad Software, San Diego, CA, USA).
Differences with P < 0.05 were considered significant.
3 | RESULTS
3.1 | Plasma, renal and liver levels of UPARANT
Subcutaneously administered UPARANT rapidly appeared in the
plasma being quantifiable at 0.25 hour, reached the Cmax at
2.3 hours, and declined following a monophasic profile. UPARANT
was still detectable at 24 hours reaching values that, although below
the lower limit of quantification, were statistically different from the
blank. These values are not represented in Figure 1 and were not
considered in evaluating PK parameters in agreement with the FDA
Guidance on Bioanalytical Method Validation.24 UPARANT was
cleared from the plasma with a t1/2 of 2.2 hours in the elimination
phase. Control values were in line with a previous work.21 No differ-
ences were found between control and STZ rats. Additional PK
parameters as evaluated using a two‐phase model equation are sum-
marized in Table S2. In the kidney of control rats, at 24 hours post-
dosing, the concentration of UPARANT was 2.2‐fold higher
(P < 0.001; 45.9 ± 3.6 μg/g) than in the liver (21.1 ± 2.4 μg/g). In
STZ rats, the liver concentration of UPARANT (20.4 ± 7.5 μg/g) did
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not differ from that in controls, whereas the UPARANT concentra-
tion in the diabetic kidney (28.2 ± 4.3 μg/g) was 1.6‐fold lower than
in controls (P < 0.01).
3.2 | The uPA/uPAR/FPR system
Representative blots of Figure 2A are indicative of the uPA/uPAR/FPR
system activation in kidney extracts. As shown by Figure 2B‐F, high
glucose enhanced renal levels of uPA and uPAR as well as uPA activity
by about 2.6‐, 4.7‐ and 2.5‐fold (P < 0.001; Figure 2B‐D), while not
affecting FPRs (Figure 2E and F). UPARANT at 1 mg/kg was ineffective
on the uPAR pathway, whereas at 8 mg/kg reduced uPA levels and
activity by 1.6‐ and 1.4‐fold (P < 0.05) without affecting uPAR levels.
In isolated glomeruli, high glucose increased FPR2 transcript (2.3‐fold;
P < 0.001) that was indeed reduced by UPARANT at 8 mg/kg (1.3‐
fold; P < 0.01; Figure 2G). In the plasma, high glucose increased uPA
levels and activity as well as (s)uPAR by 1.4‐, 1.5‐ and 1.6‐fold
(P < 0.001, Figure 2H‐J). Both uPA levels and activity, but not (s)uPAR,
were reduced by UPARANT at 8 mg/kg (1.2‐ and 1.3‐fold; P < 0.01).
3.3 | αvβ3 integrin and Rac‐1 expression and
activity
Representative blots of Figure 3A are indicative of the αvβ3 integrin
signalling pathway. As shown in Figure 3B‐D, high glucose increased
αvβ3 integrin levels and β3 integrin phosphorylation by 1.9‐ and 3.1‐
fold (P < 0.001), while not affecting Rac‐1 levels. Rac‐1 activity
increased by 2.1‐fold (P < 0.001; Figure 3E). UPARANT at 8 mg/kg,
but not at 1 mg/kg, reduced αvβ3 integrin levels and β3 integrin
phosphorylation as well as Rac‐1 activity by 1.6‐, 2.0‐ and 1.2‐fold
(P < 0.01).
3.4 | Fibrotic process
Representative blots of Figure 4A are indicative of renal levels of
secreted proteases that are known to mediate ECM remodelling. As
shown in Figure 4B‐G, high glucose increased Plg by 4.9‐fold
(P < 0.001), but decreased either plasmin levels and activity (3.0‐ and
2.1‐fold; P < 0.001) or MMP‐2/MMP‐9 levels and activity (3.1‐, 2.9‐
and 2.7‐fold; P < 0.001). UPARANT at 1 mg/kg was ineffective on
secreted proteases, while at 8 mg/kg reduced Plg levels by 1.7‐fold
(P < 0.01), increased either plasmin levels and activity by 1.5‐ and 1.7‐
fold (P < 0.01) or MMP‐2/MMP‐9 levels and activity by 2.0‐, 1.7‐ and
1.9‐fold (P < 0.01). Levels and activity of secreted proteases were also
assessed in the plasma (Figure 4H‐L). Plg levels were not affected by
hyperglycaemia that, on the contrary, reduced plasmin activity by 1.3‐
fold (P < 0.01) and increased MMP‐2/MMP‐9 levels and activity by
2.2‐, 2.4‐ and 2.2‐fold (P < 0.001). UPARANT at 8 mg/kg did not affect
Plg levels, but increased plasmin activity by 1.3‐fold (P < 0.01) without
influencing MMP‐2/MMP‐9 levels and activity. Representative blots of
Figure 4M are indicative of protein levels of ECM components. As
shown in Figure 4N‐P, high glucose increased fibronectin, collagen I
and collagen IV by 2.4‐, 7.7‐ and 2.9‐fold (P < 0.001). UPARANT at
8 mg/kg reduced fibronectin, collagen I and collagen IV by about 1.6‐,
3.1‐ and 1.8‐fold (P < 0.001) as an indirect evidence of its ameliorative
effect on fibrotic process. In agreement with these data, the histologi-
cal assessment of renal fibrosis by Masson's Trichrome staining
showed that when comparing kidney sections from STZ rats with
those from control rats, the glomerular fibrotic areas (stained in blue)
were significantly increased in STZ rats. Of note, they were decreased
by UPARANT at 8 mg/kg, but not at 1 mg/kg (Figure 4Q‐T).
3.5 | Standard renal parameters
As shown in Table 1, the bodyweight of STZ rats was 1.5‐fold lower
than in controls (P < 0.001). Both kidney weight/bodyweight and
blood glucose significantly increased by 1.6‐ and 4.2‐fold
(P < 0.001). Treatment with UPARANT at 1 or 8 mg/kg did not
affect these parameters. STZ rats also showed increased urine out-
put, urine albumin, urine creatinine, albumin to creatinine ratio,
plasma creatinine, creatinine clearance and BUN by about 10.5, 3.3‐,
1.3‐, 3.8‐, 2.2‐, 2.1‐ and 3.1‐fold, respectively (P < 0.001). UPARANT
at 1 mg/kg did not affect these parameters, whereas at 8 mg/kg
significantly reduced them by 1.7‐, 1.8‐, 1.3‐, 2.3‐, 1.4‐, 1.3‐ and
1.7‐fold, respectively (P < 0.001). No differences in systolic blood
pressure were observed among the experimental groups.
3.6 | Vascular permeability
A prediction of the vascular permeability integrity was performed by
analysing the expression levels of (a) ZO‐1 and occludin, two tight
F IGURE 1 Average plasma concentrations of UPARANT after
subcutaneous administration (20 mg/kg) to control (red dots and line)
or STZ rats (black dots and line). Continuous lines correspond to the
best fit of the equation Ct = C0(e
−kelim∙t − e−kabs∙t) where kelim and
kabs correspond to the kinetic constants of the elimination and
absorption phase, respectively. Values are expressed as means ± SD
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junction proteins participating in the glomerular filtration barrier and
(b) the propermeability factor VEGF (Figure 5A). In STZ rats, ZO‐1
(Figure 5B) and occludin (Figure 5C) decreased by 2.7‐ and 3.6‐fold
(P < 0.001) in agreement with previous studies,25 while VEGF
increased (3.9‐fold, P < 0.001; Figure 5D) in line also with previous
results.26 In addition, high glucose caused plasma extravasation as
determined by an increased amount of Evan's blue (2.2‐fold,
P < 0.001; Figure 5E). UPARANT at 1 mg/kg resulted ineffective in
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the restoration of the expression levels of these markers, whereas at
8 mg/kg both increased ZO‐1 (1.7‐fold, P < 0.01) and occludin levels
(1.8‐fold, P < 0.001), and decreased VEGF expression levels (1.8‐fold,
P < 0.001) and plasma extravasation (1.4‐fold, P < 0.05) compared
to untreated STZ rats.
Decreased plasma extravasation would result in decreased
urine output to which UPARANT‐associated increase in AQP2
expression in the medulla may contribute (Figure 6A). As shown in
Figure 6B and in line with previous findings,4 DN was associated
with relative abundance of AQP2 (2.6‐fold, P < 0.01). UPARANT at
1 mg/kg did not influence AQP2 up‐regulation, whereas at 8 mg/kg
it further increased AQP2 levels (2.8‐fold, P < 0.001). In addition,
in control rats, AQP2 was localized to the apical plasma membrane
of cells lining the collecting ducts in both the cortex and the
medulla (Figure 6C‐E). No differences between control and STZ
rats were found in the cortex (Figure 6F), while AQP2 apical
expression was higher in the medulla of STZ rats (Figure 6G and
H). UPARANT at 8 mg/kg did not influence AQP2 expression in
the cortex (Figure 6I), while further increased AQP2 immunoreac-
tivity in the medulla particularly at the apical membrane (Figure 6J
and K).
3.7 | Inflammatory markers
As shown in Figure 7 and in line with previous findings,27–29 the
levels of iNOS, ICAM‐1 and HIF‐1α, as well as the phosphorylation
F IGURE 3 UPARANT effects on αvβ3 integrin and Rac‐1. (A) Representative blots showing protein levels of pβ3 integrin (Tyr773), αvβ3
integrin and Rac‐1. β‐actin was used as the loading control. (B‐D) Densitometric analysis showing that UPARANT at 8 mg/kg, but not at 1 mg/
kg, reduced up‐regulated levels of pβ3 integrin (Tyr773) and αvβ3 integrin without affecting Rac‐1 levels. (E) Up‐regulated Rac‐1 activity was
unaffected by UPARANT at 1 mg/kg, but was decreased by UPARANT at 8 mg/kg (*P < 0.05 and **P < 0.001 vs control; §P < 0.01 and
§§P < 0.001 vs STZ; one‐way ANOVA followed by Newman‐Keuls’ multiple comparison posttest). Data are presented as scatter plots (B‐D) or
histograms (E). Each plot or histogram represents the mean ± SEM of data from three independent samples
F IGURE 2 UPARANT effects on the uPA/uPAR/FPR system. (A) Representative blots showing protein levels of uPA, uPAR, FPR2 and FPR3
in kidney extracts. β‐actin was used as the loading control. (B, D‐F) Densitometric analysis showing that UPARANT at 1 mg/kg was ineffective
on up‐regulated levels of uPA and uPAR, whereas at 8 mg/kg reduced uPA without affecting uPAR. (C) Up‐regulated uPA activity in kidney
extracts was unaffected by UPARANT at 1 mg/kg, but was decreased by UPARANT at 8 mg/kg. (G) FPR transcripts in isolated glomeruli
showing that UPARANT at 8 mg/kg, but not at 1 mg/kg, effectively reduced up‐regulated levels of FPR2 messengers. (H‐J) Up‐regulated uPA
levels and activity in the plasma were reduced by UPARANT at 8 mg/kg, but not at 1 mg/kg. Up‐regulated (s)uPAR was unaffected at any drug
concentration (*P < 0.05 and **P < 0.001 vs control; §P < 0.05 and §§P < 0.01 vs STZ; one‐way ANOVA followed by Newman‐Keuls’ multiple
comparison posttest). Data are presented as scatter plots (B, D‐F) or histograms (C, G‐J). Each plot or histogram represents the mean ± SEM of
data from three (B‐G) or seven (H‐J) independent samples
1040 | DAL MONTE ET AL.
of NF‐κB p65 at Ser276 and CREB at Ser133, were higher in STZ rats
than in controls (5.0‐, 5.6‐, 11.7‐, 10.2‐ and 6.9‐fold, respectively;
P < 0.001). Inflammatory markers were not affected by UPARANT
at 1 mg/kg, whereas UPARANT at 8 mg/kg reduced iNOS, ICAM‐1,
NF‐κB p65 phosphorylation, CREB phosphorylation and HIF‐1α by
3.0‐, 2.5‐, 3.8‐, 2.4‐ and 3.9‐fold, respectively (P < 0.001).
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3.8 | Pathological findings in the kidney
Figure 8A‐D shows the results of histological examination of kidney
sections stained with PAS. The kidneys of control rats revealed nor-
mal glomeruli (Figure 8A), while those of STZ rats (Figure 8B)
showed glomerular hypertrophy and increased mesangial area in
agreement with previous results.30 Treatment with UPARANT at
1 mg/kg was ineffective (Figure 8C), whereas UPARANT at 8 mg/kg
prevented these modifications (Figure 8D). As shown by the quanti-
tative analysis, the glomerular area (Figure 8E) and the mesangial
area (Figure 8F) were increased by 1.2‐ and 1.3‐fold (P < 0.001) as
compared to controls. These parameters were reduced by UPARANT
at 8 mg/kg by 1.1‐ and 1.2‐fold (P < 0.001), while no effects were
observed after UPARANT at 1 mg/kg. The characteristic alterations
of DN are well evident in the TEM representative images of Fig-
ure 8G‐J. In particular, their qualitative analysis demonstrates thick-
ening of the glomerular basement membrane and loss of podocyte
foot processes as shown by the increase in their base width and the
reduction in their number. UPARANT at 1 mg/kg was ineffective,
whereas at 8 mg/kg prevented the modifications of the glomerular
filtration barrier by almost restoring the normal architecture.
4 | DISCUSSION
This paper provided the first evidence that blocking the uPAR path-
way with UPARANT, a small peptide with a predominant anti‐inflam-
matory action, can improve diabetic kidney lesion in rats. The
efficacy of UPARANT in DN suggests a pivotal role of the uPAR sys-
tem in the pathogenesis of diabetic complications, such as DN and
DR that share similar pathogenesis mechanisms including dysregu-
lated uPAR pathway. In this respect, the possible use of drugs tar-
geting mechanisms common to DN and DR is of increasing interest
to treat both diabetes complications at the same time. In addition,
whether drugs regulating uPAR activation might be administered in
association with hypoglycaemic drugs, then the possibility can be
hypothesized that diabetes‐associated renal complications can be
retarded or even abolished.
4.1 | UPARANT delivery and administration
regimen
As shown here, the plasma concentration of UPARANT is compara-
ble in control and STZ rats in line with previous results21 and with
TABLE 1 Physiological and renal parameters
Control STZ STZ + UPARANT, 1 mg/kg STZ + UPARANT, 8 mg/kg
Bodyweight (g) 373.7 ± 2.7 245.2 ± 2.6* 246.3 ± 4.0* 248.3 ± 3.0*
Kidney weight/Bodyweight (mg/g) 2.64 ± 0.12 4.26 ± 0.09* 4.13 ± 0.08* 4.03 ± 0.08*
Blood glucose (mg/dL) 127.2 ± 5.5 529.8 ± 18.3* 539.3 ± 20.3* 563.5 ± 11.7*
Urine output (mL) 15.6 ± 0.9 163.1 ± 7.2* 158.7 ± 6.2* 94.4 ± 1.9*,†
Urine albumin (mg/24 h) 0.628 ± 0.013 2.088 ± 0.047* 2.080 ± 0.079* 1.178 ± 0.039*,†
Urine creatinine (mg/24 h) 13.43 ± 0.25 17.40 ± 0.41* 17.27 ± 0.45* 13.36 ± 0.26†
Albumin to creatinine ratio 0.041 ± 0.001 0.154 ± 0.005* 0.153 ± 0.003* 0.066 ± 0.002*,†
Plasma creatinine (mg/mL) 0.430 ± 0.017 0.937 ± 0.043* 0.925 ± 0.042* 0.653 ± 0.048*,†
Creatinine clearance (μL/min/g) 3.521 ± 0.177 7.560 ± 0.290* 7.366 ± 0.382* 5.976 ± 0.313*,†
Blood urea nitrogen (mmol/L) 7.71 ± 0.20 23.82 ± 0.50* 23.25 ± 0.41* 13.85 ± 0.40*,†
Systolic blood pressure (mmHg) 125.4 ± 5.1 127.3 ± 1.9 130.3 ± 3.4 127.4 ± 3.9
*P < 0.001 vs control; †P < 0.001 vs STZ (one‐way ANOVA followed by Newman‐Keuls’ multiple comparison posttest).
F IGURE 4 UPARANT effects on renal fibrosis. (A) Representative blots showing protein levels of Plg, plasmin, MMP‐2 and MMP‐9 in
kidney extracts. β‐actin was used as the loading control. (B, C, E, F) Densitometric analysis showing that UPARANT at 8 mg/kg, but not at
1 mg/kg, almost recovered dysregulated levels of Plg, plasmin, MMP‐2 and MMP‐9. (D, G) Down‐regulated activity of both plasmin and
MMPs was unaffected by UPARANT at 1 mg/kg, but was increased by UPARANT at 8 mg/kg. (H‐L) In the plasma, Plg levels, plasmin
activity, MMP‐2 and MMP‐9 levels and their activity were unaffected by UPARANT with the exception of plamin activity that was
recovered by UPARANT at 8 mg/kg. (M) Representative blots showing protein levels of ECM components including fibronectin, collagen I
and collagen IV. β‐actin was used as the loading control. (N‐P) Densitometric analysis showing that UPARANT at 8 mg/kg, but not at 1 mg/
kg, reduced up‐regulated levels of ECM components (*P < 0.01 and **P < 0.001 vs control; §P < 0.01 and §§P < 0.001 vs STZ; one‐way
ANOVA followed by Newman‐Keuls’ multiple comparison posttest). Data are presented as scatter plots (B, C, E, F, N‐P) or histograms (D,
G, H‐L). Each plot or column represents the mean ± SEM of data from three (B‐G, N‐P) or seven (H‐L) independent samples. (Q‐T)
Histological assessment of renal fibrosis in control (Q) and STZ rats either untreated (R) or treated with UPARANT at 1 mg/kg (S) or 8 mg/
kg (T). Representative photomicrographs from Masson's Trichrome staining of sections that are representative of three animals/group
showing that increased glomerular fibrotic areas (stained in blue) were reduced by UPARANT at 8 mg/kg, but not at 1 mg/kg. Scale bar:
50 μm
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the fact that systemically delivered drugs have been found to display
comparable PK profiles in healthy and diabetic rats.31,32 Tissue
UPARANT concentration found here reflects a major role of the kid-
ney in regulating drug distribution and metabolism. The lower UPAR-
ANT concentration found in the diabetic kidney suggests that
altered kidney function may affect the excretion of the compound
that, although filtered at the glomerular level, may be reabsorbed by
the tubules, thus shifting its elimination route. UPARANT dose and
regimen used here are in line with those used in previous studies in
which systemic treatment with the drug has been shown both effec-
tive and safe.21,22 In particular, UPARANT dosage is almost 50% less
than that used in the PK study and is in line with the UPARANT
concentration measured in the kidney.
4.2 | Recovery of the uPA/uPAR/FPR system
Increased activation of the uPAR pathway and increased (s)uPAR
levels are indicative of uPA/uPAR contribution to a proteolytic cas-
cade that has detrimental effects on glomerular cell permeability.33
In addition, FPR2 overexpression found here in isolated glomeruli is
in line with FPR accumulation in models of impaired nephrogenesis
in which FPR2, in particular, appears to participate to the fibrosis
process.34,35 As shown by the present results, UPARANT efficacy
against diabetic kidney lesion is associated to decreased uPA accu-
mulation and activity, thus presumably influencing ligand availability
to its receptors and increasing drug efficacy more than if the drug
acted at the postreceptor level only. In this line, there is evidence
that reducing uPA‐uPAR interactions results in beneficial effects on
kidney lesions.36,37 As also shown here, UPARANT does not affect
(s)uPAR up‐regulation in agreement with previous findings demon-
strating that blockers of the renin angiotensin system commonly
used to prevent or delay DN do not affect plasma (s)uPAR in dia-
betic patients.38 The additional finding that the drug does not influ-
ence uPAR in podocytes is in line with the possibility that
UPARANT acts downstream uPAR by presumably blocking its bind-
ing to FPRs. In this respect, UPARANT has been designed to mimic
the sequence through which uPAR not only interacts with FPRs
thus competing with FPR ligands,15 but also binds vitronectin thus
activating αvβ3 integrin39 that is indeed forced into an inactive
state.15
F IGURE 5 UPARANT effects on vascular permeability markers and Evans blue dye leakage. (A) Representative blots showing protein levels
of ZO‐1, occludin and VEGF. β‐actin was used as the loading control. (B‐D) Densitometric analysis showing that UPARANT at 8 mg/kg, but not
at 1 mg/kg, increased ZO‐1 and occludin while decreased VEGF. (E) Quantitative evaluation of Evans blue extravasation. Increased Evans blue
dye that was almost recovered by UPARANT at 8 mg/kg but not at 1 mg/kg (*P < 0.01 and **P < 0.001 vs control; §P < 0.05, §§P < 0.01 and
§§§P < 0.001 vs STZ; one‐way ANOVA followed by Newman‐Keuls’ multiple comparison posttest). Data are presented as scatter plots (B‐D) or
histograms (E). Each plot or column represents the mean ± SEM of data from three independent samples
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4.3 | Recovery of kidney lesions
Plg is mainly synthesized in the liver, circulates in the plasma and is
activated to plasmin by a finely tuned balance between activators,
including uPA, and inhibitors: a dysregulation of this system is
reported in renal diseases, including DN, but the mechanisms
through which it contributes to diabetic kidney lesions are not still
completely understood.9 The present finding that UPARANT recov-
ers, at least in part, plasmin activity is indicative of the possibility
that the drug may reinstate the physiological balance between acti-
vators and inhibitors, thus reactivating the proteolytic cascade that
leads to the degradation of ECM components. The main regulators
of ECM degradation in the glomerulus are MMPs, being a balance
between ECM synthesis and degradation a prerequisite to maintain
glomerulus integrity. In particular, MMP‐2 and MMP‐9 are consid-
ered as the main enzymes degrading collagen IV, the major collage-
nous component of ECM constituting the architectural structure of
glomerular basement membrane.40 Thus, high glucose‐induced reduc-
tion in renal MMPs as observed here, may be directly translated into
altered ECM turnover and is consistent with the increased deposi-
tion of ECM components leading to glomerular damage and a
decline in renal function.41 As also shown here, high glucose
increases plasma levels and activity of MMP‐2/MMP‐9 in line with
previous findings in diabetic patients with abnormal ECM metabo-
lism.42 The present finding that at the renal level UPARANT counter-
acts high glucose‐associated dysregulation of MMPs is indicative of
its major effects on ECM‐degrading proteases. This is in line with
the fact that increased uPA/uPAR expression correlates well with
ECM accumulation in STZ rats,43 while uPAR knockdown reduces
MMPs expression in cultured kidney cells.44 The finding that UPAR-
ANT does not affect plasma MMPs suggests the predominance of
local effects on MMPs‐expressing podocytes45 over systemic effects
on secreted proteases also in line with previous studies using antiox-
idative compounds in the STZ model.46 As a consequence of the
restored MMPs activity, UPARANT reduces renal fibrosis as indi-
rectly evidenced by decreased levels of ECM components and
directly observed by the marked reduction of Masson's staining. This
is in line with previous findings demonstrating that drugs
A
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F IGURE 6 UPARANT effects on AQP2 expression and localization. (A) Representative blots showing protein levels of AQP2 in the kidney
medulla. β‐actin was used as the loading control. (B) Densitometric analysis showing that UPARANT at 8 mg/kg increased high glucose‐induced
AQP2 up‐regulation, while it was ineffective at 1 mg/kg (*P < 0.01 and **P < 0.001 vs control; §P < 0.001 vs STZ; one‐way ANOVA followed by
Newman‐Keuls’ multiple comparison posttest). Data are presented as scatter plots. Each plot represents the mean ± SEM of data from three
independent samples. (C‐K) AQP2 immunoreactivity in control (C‐E) and STZ rats either untreated (F‐H) or treated with UPARANT 8 mg/kg (I‐K).
Representative photomicrographs from sections that are representative of three animals/group showing that AQP2 is expressed at the apical plasma
membrane of cells lining the collecting ducts of the cortex (C) and the medulla (outer in D and inner in E). STZ did not modify AQP2 expression in
the cortex (F), whereas increased the apical expression of AQP2 in the medulla (outer in G and inner in H). UPARANT at 8 mg/kg did not change
AQP2 expression in the cortex (I), whereas additionally increased AQP2 apical expression in the medulla (outer in J and inner in K). Scale bar: 50 μm
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F IGURE 7 UPARANT effects on inflammatory markers. (A) Representative blots showing protein levels of iNOS, ICAM‐1, pNF‐kB p65
(Ser276), NF‐kB p65, pCREB (Ser133), CREB and HIF‐1α. β‐actin was used as the loading control. (B‐H) Densitometric analysis showing that
UPARANT at 8 mg/kg, but not at 1 mg/kg, reduced up‐regulated levels of iNOS, ICAM‐1, pNF‐kB p65 (Ser276), pCREB (Ser133) and HIF‐1α
(*P < 0.05, **P < 0.001 and ***P < 0.001 vs control; §P < 0.001 vs STZ; one‐way ANOVA followed by Newman‐Keuls’ multiple comparison
posttest). Data are presented as scatter plots. Each plot represents the mean ± SEM of data from three independent samples
F IGURE 8 Effects of UPARANT on glomerular morphology and filtration barrier. (A‐D) Representative histological sections stained with
periodic acid‐Schiff of kidneys from control (A) and STZ rats either untreated (B) or treated with UPARANT at 1 mg/kg (C) or 8 mg/kg (D).
UPARANT at 1 mg/kg did not affect the glomerular morphology (C), whereas at 8 mg/kg attenuated glomerular hypertrophy and mesangial
expansion (D). Scale bar: 50 μm. (E, F) Quantitative evaluation of glomerular hypertrophy (E) and increased mesangial area (F) confirmed
qualitative assessment (*P < 0.05 and **P < 0.001 vs control; §P < 0.001 vs STZ; one‐way ANOVA followed by Newman‐Keuls’ multiple
comparison posttest). Data are presented as histograms. Each column represents the mean ± SEM of data from 15 glomerular sections (five
sections/animal, three animals/group). (G‐J) UPARANT effects on glomerular filtration barrier morphology. EM micrographs at 30 K
magnification that are representative of three animals/group showing ultrathin podocyte sections from control (G) or STZ rats either untreated
(H) or treated with UPARANT at 1 mg/kg (I) or 8 mg/kg (J). UPARANT at 8 mg/Kg, but not at 1 mg/kg, reduced high glucose‐induced thickening
of the glomerular basement membrane and almost recovered foot process effacement. Scale bar: 500 nm
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counteracting MMPs dysregulation are found to inhibit ECM accu-
mulation, thus preventing glomerular damage in STZ rats.47,48 To the
best of our knowledge, this is the first report indicating that inhibit-
ing the uPAR pathway restores MMPs, thus suggesting a possible
mechanism through which UPARANT may act to maintain the struc-
tural and functional integrity of the glomerulus. As also observed
here, the UPARANT‐induced recovery of impaired glomerular func-
tion seems to be the fundamental way to lower altered renal
A
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parameters. In particular, recovered proteinuria is in line with uPAR
role in regulating the αvβ3 integrin/Rac‐1 pathway and suggests the
possibility that uPAR interacts with αvβ3 integrin receptors to affect
podocyte function.10 Indeed, as shown here, up‐regulated levels of
αvβ3 integrin and increased Rac‐1 activity are recovered by UPAR-
ANT indicating a major role of uPAR (as well as (s)uPAR from circula-
tion) to regulate the αvβ3 integrin/Rac‐1 pathway in podocytes. In
this respect, induction of uPAR signalling in podocytes leads to foot
process effacement and urinary protein loss via a mechanism that
includes the activation of the αvβ3 integrin/Rac‐1 pathway.36 Thus,
preventing uPAR/(s)uPAR interactions with αvβ3 integrin is likely to
affect the activation of the αvβ3 integrin/Rac‐1 pathway and the
uPAR/(s)uPAR‐mediated podocyte injury.10 Ameliorative effects upon
the inhibition of the uPAR pathway are in agreement with the find-
ing that uPAR down‐regulation restores the filtration barrier function
in cultured podocytes49 and reduces proteinuria in lipopolysaccha-
ride‐treated mice.36,37 This is also in line with the present finding
that UPARANT‐induced recovery of altered vascular permeability is
established through restored levels of tight junction proteins and
inhibition of VEGF production. These results together suggest an
additional mechanism through which the uPAR pathway negatively
affects glomerular filtration and are in line with previous findings
demonstrating that deletion of various components of the uPA/uPAR
system is protective against vascular changes in models of renal dis-
eases.9 Recovered vascular permeability is associated with UPAR-
ANT‐induced increase of AQP2 in the medulla in which AQP2 seems
to prevent excessive water loss through urine.4 In this respect, ther-
apies that up‐regulate AQP2 expression in the inner medulla have
been shown to prevent diabetic kidney disease.50 Additional effects
of UPARANT include its potent anti‐inflammatory action. This is par-
ticularly interesting since inflammation has been shown to play a
major role in diabetic kidney disease and the suboptimal efficacy of
the current therapeutic strategies may depend on their limited
impact on inflammatory processes.51 Flavonoids, for instance, have
been shown to attenuate DN more efficiently than commercial
antidiabetic drugs via suppressing the activation of NF‐κB and
decreasing ICAM‐1 and iNOS.52,53 As shown here, UPARANT inhi-
bits up‐regulated levels of NF‐κB, which, in addition to activate gene
transcription of inflammatory factors,54 promotes uPA transcription55
and regulates ECM production.56 In addition, NF‐κB regulation of
ICAM‐1 positively correlates with nephropathy57 by influencing
mesangial cell proliferation.58 Moreover, NF‐κB participates to iNOS
accumulation59 and, together with CREB, regulates AQP2 gene tran-
scription.60 Whether UPARANT‐induced inhibition of HIF‐1α accu-
mulation ameliorates kidney disease remains unclear as to some
extent the activation of HIF‐1, but not its inhibition, seems to exert
a beneficial role in the progression of DN.61 Suppression of inflam-
matory processes and ameliorated renal fibrosis results in recovered
renal morphology as shown here by the reduction of glomerular
hypertrophy and mesangial area increase.62 Additional efficacy of
UPARANT includes ameliorated renal filtration barrier as demon-
strated by recovery from increased thickness of glomerular basement
membrane and from loss of podocyte foot processes leading to
proteinuria. Consistently, the observed reduction in the urine albu-
min level in UPARANT‐treated rats is congruent with UPARANT‐
induced protection of the renal architecture.
5 | CONCLUSION
Together, the present findings support the possibility that uPA/uPAR
activation in response to high glucose participates in the mechanisms
causing DN and provide evidence that the uPAR pathway is a
promising target for the development of novel multitarget drugs in
the treatment of diabetic kidney disease. By acting on multiple path-
ways involved in DN pathogenesis, UPARANT constitutes a promis-
ing strategy to cure the diseased kidney although the extrapolation
of these experimental findings to the clinic is not straightforward.
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